Comment

Sanofi and GSK announced an agreement with Canada to supply up to 72 million doses while reports suggest the US FDA will only grant emergency authorisation to COVID-19 vaccines with two months follow-up.

Joe Damond, the executive vice president of international affairs at US-based BIO, told BioPharmaDispatch the Trump administration's move on pricing is based on its view the industry takes the US for granted and is too quick to accept low prices in countries like Australia.

The managing director of MSD Australia, Michael Azrak, said the paper comes at a critical time given AMR remains a global health priority.

A new global report on flu vaccination says Australia has a strong national program but that more needs to be done to communicate its importance to some prioritised groups.

Australians living with obesity are waiting up to almost a decade to access care, according to new global research supported by Novo Nordisk.

New Zealand's Human Rights Commission has intervened in a case involving the country's controversial medicines purchasing agency PHARMAC.

Some well-known PBS medicines, including for the treatment of cancer and macular degeneration, could be impacted if President Trump's order proceeds to implementation.

Kazia Therapeutics, an Australian oncology-focused biotechnology company, has announced a new collaboration with the US-based Dana-Farber Cancer Institute.

Melbourne-based company Neuren Pharmaceuticals says it has initiated the manufacture of NNZ-2591 to supply planned phase two clinical trials.

The government has arguably met its consultation obligations and can proceed with any change even if the industry associations 'walk away' from the process.

NPS MedicineWise is refusing to answer any questions on the report of the review of its operation led by former PBAC chair Emeritus Professor Lloyd Sansom AO while it is possible its controversial commercial arm VentureWise is actually still operating.

The report of the NPS MedicineWise review found the government's grant was funding some costs the organisation was then passing on to non-government clients of VentureWise. These clients paid these costs that were then retained by NPS MedicineWise.